Patients with diabetes mellitus, Acquired Immune Deficiency Syndrome (AIDS), chronic systemic corticosteroid usage, chemotherapy-induced neutropenia, or IL-23/ IL-17A blockade for the treatment of autoimmune diseases such as rheumatoid arthritis, as well as patients at ICU or with impaired immunity are predisposed to chronic mucosal and cutaneous candidiasis (CMC) or even systemic candidiasis, leading to significant morbidity and greater than 50% mortality [1–9]. Here, IL17A is linked to AIDS.